Bicycle Therapeutics Presents Posters at the SITC 35th Anniversary Annual Meeting

Dovie Salais

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that preclinical data for BT7480, a tumor-targeted immune cell agonist (TICA™), and an EphA2/CD137 TICA will be presented during an […]

Bicycle Therapeutics Announces Expansion of Scientific Advisory Board

Dovie Salais

– Four renowned experts join to advise Bicycle as the company advances pipeline of novel cancer therapeutic candidates Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that leaders in the fields of oncology, […]

Bicycle Therapeutics Announces Gross Proceeds of $50.0 Million from its At-the-Market Offering Program and Enters into Debt Financing from Hercules Capital

Dovie Salais

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has completed its at-the-market (ATM) offering program initiated during the third quarter, generating gross proceeds of $50.0 million. […]

Bicycle Therapeutics Announces Pipeline Progress Update

Dovie Salais

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced progress updates across its wholly-owned and partnered programs in oncology and non-oncology indications. “We and our partners have recently achieved […]

Bicycle Therapeutics partners with Roche

Dovie Salais

Bicycle Therapeutics, a Cambridge, UK-based biotech, developing proprietary bicyclic peptides has attracted the attention of Roche subsidiary, Genentech. The two companies agreed a collaboration agreement, with Bicycle receiving $30m (€27.4m) in an upfront fee and eligible for a further $1.7bn (€1.55bn) dependent upon milestones met. The focus will be on […]

Subscribe US Now